AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26098748 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib (BKM120) 100 mg/day
Number of subjects: 63
Study 26099302 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronal ensemble activity in motor cortex
Number of subjects: 2
Study 26100297 — intervention group
Group type: EXPERIMENTAL
Intervention: EMR alert and referral system
Number of subjects: 354
Study 26100297 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling on teratogen exposure and contraception
Number of subjects: 354
Study 26100297 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 354
Study 26100447 — intervention group
Group type: EXPERIMENTAL
Intervention: f/b EVAR
Number of subjects: 268
Study 26100447 — intervention group
Group type: COMPARATOR
Intervention: OSR
Number of subjects: 268
Study 26100711 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D regimen with ribavirin (RBV) for 8, 12, or 24 weeks
Number of subjects: 406
Study 26100711 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D regimen without ribavirin (RBV) for 8, 12, or 24 weeks
Number of subjects: 406
Study 26100711 — intervention group
Group type: EXPERIMENTAL
Intervention: Paritaprevir-ritonavir dose of 150/100 mg
Number of subjects: 406
Study 26100711 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment duration of 12 or more weeks
Number of subjects: 406
Study 26100711 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment duration of 8 weeks
Number of subjects: 406
Study 26100928 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR) for 6 weeks followed by a 6-week weight stabilisation diet
Number of subjects: 49
Study 26100928 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline A. muciniphila abundance
Number of subjects: 49
Study 26100928 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher gene richness
Number of subjects: 49
Study 26100928 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline A. muciniphila abundance
Number of subjects: 49
Study 26100975 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb™ BVS
Number of subjects: 1000
Study 26101020 — intervention group
Group type: EXPERIMENTAL
Intervention: PET CT
Number of subjects: 20
Study 26101247 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 5 mg per day with ovarian stimulation and embryo cryopreservation
Number of subjects: 131
Study 26103565 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based telemental health treatment (behavioral activation treatment)
Number of subjects: 10
Study 26103598 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (100 mg day(-1))
Number of subjects: 52
Study 26104319 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body computed tomography (WBCT)
Number of subjects: 9
Study 26104319 — intervention group
Group type: COMPARATOR
Intervention: Conventional diagnostics (CR and FAST)
Number of subjects: 9
Study 26104746 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous arrhythmia ablation
Number of subjects: 25
Study 26104746 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive interviews
Number of subjects: 25
Study 26104945 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT (Stereotactic Body Radiation Therapy)
Number of subjects: 0
Study 26105029 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of care for patients hospitalised with ACS
Number of subjects: 5556
Study 26105029 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measures of health-related quality of life
Number of subjects: 5556
Study 26105029 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about medications and patient adherence profiles
Number of subjects: 5556
Study 26105029 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey of hospital facilities
Number of subjects: 5556
Study 26105029 — intervention group
Group type: EXPERIMENTAL
Intervention: Morbidity and mortality data from electronic health records
Number of subjects: 5556
Study 26105149 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiating treatment at diagnosis
Number of subjects: 2652
Study 26105149 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
Number of subjects: 2652
Study 26105149 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance rituximab
Number of subjects: 2652
Study 26105149 — intervention group
Group type: COMPARATOR
Intervention: Patients with transformation
Number of subjects: 2652
Study 26105149 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transformation overall survival
Number of subjects: 2652
Study 26106964 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus localization in the main pulmonary arteries
Number of subjects: 148
Study 26106964 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus localization in immobile patients
Number of subjects: 148
Study 26106964 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer levels and red blood cell distribution width in patients with thrombi in main pulmonary arteries
Number of subjects: 148
Study 26106964 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal thrombi associations
Number of subjects: 148
Study 26108094 — intervention group
Group type: EXPERIMENTAL
Intervention: DXA (absolute BMD and Z-score)
Number of subjects: 57
Study 26108094 — intervention group
Group type: EXPERIMENTAL
Intervention: pQCT (volumetric BMD [vBMD] and stress-strain index [SSI])
Number of subjects: 57
Study 26108094 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory evaluation and questionnaire administration
Number of subjects: 57
Study 26109496 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum oxytocin (OT) levels
Number of subjects: 552
Study 26109579 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dietary glycemic index (GI)
Number of subjects: 87618
Study 26109579 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher consumption of dietary added sugars
Number of subjects: 87618
Study 26109579 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher consumption of lactose, fiber, nonjuice fruit, and vegetables
Number of subjects: 87618
Study 26109579 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonwhole/refined grain consumption
Number of subjects: 87618
Study 26109588 — intervention group
Group type: EXPERIMENTAL
Intervention: guided high MI/half tPA (0.5 mg/kg tPA with guided high MI impulses)
Number of subjects: 32
Study 26109588 — intervention group
Group type: EXPERIMENTAL
Intervention: full-dose tPA (1.0 mg/kg tPA)
Number of subjects: 32
Study 26109588 — intervention group
Group type: EXPERIMENTAL
Intervention: guided high MI alone (without tPA)
Number of subjects: 32
Study 26109588 — intervention group
Group type: COMPARATOR
Intervention: half dose tPA (control group)
Number of subjects: 32
Study 26109588 — intervention group
Group type: EXPERIMENTAL
Intervention: guided high MI/half tPA
Number of subjects: 32
Study 26109588 — intervention group
Group type: EXPERIMENTAL
Intervention: full-dose tPA
Number of subjects: 32
Study 26109631 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m(2)), Cisplatin (75 mg/m(2)), and Cetuximab (250 mg/m(2) weekly with a loading dose of 400 mg/m(2)), followed by maintenance Cetuximab (500 mg/m(2) every 2 weeks)
Number of subjects: 54
Study 26109631 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel, Cisplatin, and Cetuximab (TPEx regimen)
Number of subjects: 54
Study 26109816 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus XELOX
Number of subjects: 197
Study 26109878 — intervention group
Group type: EXPERIMENTAL
Intervention: sunitinib plus mFOLFOX6
Number of subjects: 191
Study 26109878 — intervention group
Group type: COMPARATOR
Intervention: bevacizumab plus mFOLFOX6
Number of subjects: 191
Study 26109993 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU/week for 6 months)
Number of subjects: 52
Study 26109993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 26109993 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and Placebo
Number of subjects: 52
Study 26110670 — intervention group
Group type: EXPERIMENTAL
Intervention: Different SMBG systems (7 systems tested)
Number of subjects: 0
Study 26110670 — intervention group
Group type: COMPARATOR
Intervention: Comparison measurement with glucose oxidase method (YSI 2300 STAT Plus™)
Number of subjects: 0
Study 26110670 — intervention group
Group type: COMPARATOR
Intervention: Comparison measurement with hexokinase method (cobas Integra(®) 400 Plus)
Number of subjects: 0
Study 26110670 — intervention group
Group type: EXPERIMENTAL
Intervention: ISO 15197:2003 accuracy criteria
Number of subjects: 0
Study 26111071 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjudication Committee (AC) review of suspected acute exacerbations (AExs)
Number of subjects: 1015
Study 26111071 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjudication Committee (AC) review of nonelective hospitalizations
Number of subjects: 1015
Study 26111071 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjudication Committee (AC) review of cases of bleeding
Number of subjects: 1015
Study 26111071 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjudication Committee (AC) role in determining adverse outcomes
Number of subjects: 1015
Study 26111103 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis (guideline-recommended)
Number of subjects: 113
Study 26111297 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive for Giardia intestinalis (n=39)
Number of subjects: 74
Study 26111297 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity of Giardia intestinalis infection
Number of subjects: 74
Study 26111297 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal ELISA assay for G intestinalis
Number of subjects: 74
Study 26111330 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited dissection abdominoplasty
Number of subjects: 22
Study 26111330 — intervention group
Group type: COMPARATOR
Intervention: Full dissection abdominoplasty
Number of subjects: 22
Study 26111920 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step triage test including simple ultrasound-based rules
Number of subjects: 270
Study 26111920 — intervention group
Group type: COMPARATOR
Intervention: Risk of Malignancy Index (RMI) with a cut-off value of 200
Number of subjects: 270
Study 26112004 — intervention group
Group type: EXPERIMENTAL
Intervention: Oraxol (paclitaxel 150 mg/m(2) per day + HM30181A 15 mg/day)
Number of subjects: 43
Study 26112099 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered icatibant
Number of subjects: 170
Study 26112099 — intervention group
Group type: COMPARATOR
Intervention: HCP-administered icatibant
Number of subjects: 170
Study 26112223 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric oral antibiotic therapy
Number of subjects: 152
Study 26113170 — intervention group
Group type: EXPERIMENTAL
Intervention: OPACH algorithm
Number of subjects: 175
Study 26113170 — intervention group
Group type: COMPARATOR
Intervention: Visual inspection
Number of subjects: 175
Study 26113170 — intervention group
Group type: COMPARATOR
Intervention: Participant logs
Number of subjects: 175
Study 26114455 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced aerobic exercise (FE) on a motorized stationary bicycle followed by upper-extremity repetitive task practice, 24 training sessions of 45 min each.
Number of subjects: 1
Study 26114817 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative optical coherence tomography (OCT)
Number of subjects: 0
Study 26114817 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscope-mounted spectral domain optical coherence tomography system
Number of subjects: 0
Study 26114817 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative optical coherence tomography
Number of subjects: 0
Study 26115532 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 110
Study 26115532 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 110
Study 26115532 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 110
Study 26115532 — intervention group
Group type: EXPERIMENTAL
Intervention: Unwanted treatment (any of the above therapies) in comorbidly depressed patients
Number of subjects: 110
Study 26115532 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment preference/disinclination
Number of subjects: 110
Study 26115532 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment preference
Number of subjects: 110
Study 26115881 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV treatment
Number of subjects: 124
Study 26116126 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1034702 (5 mg oral dose)
Number of subjects: 6
Study 26116126 — intervention group
Group type: EXPERIMENTAL
Intervention: [(11)C]GSK1034702 (intravenous injection)
Number of subjects: 6
Study 26116238 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with Paclitaxel and Trastuzumab for HER2-positive patients
Number of subjects: 78
Study 26116238 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with Docetaxel and Epirubicin for HER2-negative patients
Number of subjects: 78
Study 26116238 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological complete response (pCR)
Number of subjects: 78
Study 26116469 — intervention group
Group type: EXPERIMENTAL
Intervention: ERCP with cholangioscopy
Number of subjects: 57
Study 26116469 — intervention group
Group type: EXPERIMENTAL
Intervention: ERCP with cholangioscopy with biopsy sampling
Number of subjects: 57
Study 26116658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg daily and 12 doses of ofatumumab 300/2000 mg (Group 1; n = 27)
Number of subjects: 71
Study 26116658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg daily and 12 doses of ofatumumab 300/2000 mg (Group 2; n = 20)
Number of subjects: 71
Study 26116658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg daily and 12 doses of ofatumumab 300/2000 mg (Group 3; n = 24)
Number of subjects: 71
Study 26116658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg daily and 12 doses of ofatumumab 300/2000 mg (all groups)
Number of subjects: 71
Study 26116722 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Number of subjects: 0
Study 26116722 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 26117461 — intervention group
Group type: EXPERIMENTAL
Intervention: ARTO system
Number of subjects: 11
Study 26119560 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG) administered according to the Southwest Oncology Group protocol.
Number of subjects: 130
Study 26119560 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine panel (nomogram CyPRIT) using urinary levels of nine inducible cytokines (IL-2, IL-6, IL-8, IL-18, IL-1ra, TRAIL, IFN-γ, IL-12[p70], and TNF-α).
Number of subjects: 130
Study 26120369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26121348 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 5 or 10 mg once daily
Number of subjects: 31
Study 26121347 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 5 or 10 mg daily (< 20 kg) or 10 or 20 mg daily (≥ 20 kg) for 8 weeks
Number of subjects: 109
Study 26121347 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 109
Study 26121349 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (2.5-10 mg once daily for 2 weeks, then weight-adjusted doses for 4 weeks)
Number of subjects: 98
Study 26121349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 26121349 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 98
Study 26121349 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole and Placebo
Number of subjects: 98
Study 26121490 — intervention group
Group type: EXPERIMENTAL
Intervention: FAIM3:PLAC8 gene expression ratio
Number of subjects: 334
Study 26123033 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0
Study 26123189 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and nab-paclitaxel every 21 days
Number of subjects: 63
Study 26123421 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulse oscillometry (IOS) during bronchial challenge testing with inhaled methacholine
Number of subjects: 0
Study 26123421 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulse oscillometry (IOS) during bronchial challenge testing with inhaled histamine
Number of subjects: 0
Study 26123421 — intervention group
Group type: COMPARATOR
Intervention: Spirometry (FEV1) during bronchial challenge testing with inhaled methacholine
Number of subjects: 0
Study 26123563 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Number of subjects: 0
Study 26123563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26123660 — intervention group
Group type: EXPERIMENTAL
Intervention: sNox2-dp levels in patients with AF
Number of subjects: 432
Study 26123660 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonia Severity Index score
Number of subjects: 432
Study 26123660 — intervention group
Group type: EXPERIMENTAL
Intervention: History of paroxysmal AF
Number of subjects: 432
Study 26123660 — intervention group
Group type: EXPERIMENTAL
Intervention: sNox2-dp levels
Number of subjects: 432
Study 26123660 — intervention group
Group type: EXPERIMENTAL
Intervention: sNox2-dp levels at discharge
Number of subjects: 432
Study 26123660 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who returned to sinus rhythm
Number of subjects: 432
Study 26123660 — intervention group
Group type: EXPERIMENTAL
Intervention: sNox2-dp levels in patients remaining in AF
Number of subjects: 432
Study 26123926 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivantinib (360 mg po bid)
Number of subjects: 22
Study 26123937 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-tablet FTC-RPV-TDF once daily for 28 days
Number of subjects: 100
Study 26124071 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and brief intervention (SBI)
Number of subjects: 553
Study 26124085 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group investigation
Number of subjects: 16
Study 26124112 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain functional connectivity states computed within windows of 22.5 seconds
Number of subjects: 0
Study 26124112 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatially restricted functional connectivity information
Number of subjects: 0
Study 26124112 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest task performance subjects
Number of subjects: 0
Study 26124477 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-1008 (tigatuzumab)
Number of subjects: 19
Study 26126206 — intervention group
Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND)
Number of subjects: 64
Study 26126668 — intervention group
Group type: EXPERIMENTAL
Intervention: HEV 239 vaccine
Number of subjects: 1278
Study 26126727 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR + Gemcitabine
Number of subjects: 20
Study 26126727 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 20
Study 26129726 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced group of surgeons (n = 12)
Number of subjects: 19
Study 26129726 — intervention group
Group type: COMPARATOR
Intervention: Novice group of surgeons (n = 7)
Number of subjects: 19
Study 26130053 — intervention group
Group type: EXPERIMENTAL
Intervention: Perimesencephalic SAH (PM-SAH)
Number of subjects: 173
Study 26130053 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-perimesencephalic SAH (NPM-SAH)
Number of subjects: 173
Study 26130053 — intervention group
Group type: EXPERIMENTAL
Intervention: Fisher 3 blood pattern group
Number of subjects: 173
Study 26130053 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without Fisher 3 blood pattern
Number of subjects: 173
Study 26130259 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft tissue thickening in thin bone phenotypes after 8 weeks of healing
Number of subjects: 0
Study 26130259 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft tissue dimensions in thick bone phenotypes after 8 weeks of healing
Number of subjects: 0
Study 26130259 — intervention group
Group type: COMPARATOR
Intervention: Total tissue loss comparison between thin and thick bone phenotypes
Number of subjects: 0
Study 26130259 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimensional alterations within the first 2 weeks of healing
Number of subjects: 0
Study 26131835 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific complaints (NSC) patients
Number of subjects: 1210
Study 26131835 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific complaints (NSC) patients with acute morbidity (heart failure and pneumonia)
Number of subjects: 1210
Study 26131835 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific complaints (NSC) patients lacking acute morbidity but suffering from functional impairment or depression/anxiety
Number of subjects: 1210
Study 26132091 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 0
Study 26132091 — intervention group
Group type: COMPARATOR
Intervention: Non-CSCs
Number of subjects: 0
Study 26132314 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (500 mg/m2), two infusions two weeks apart, followed by maintenance infusions after 3, 6, 10 and 15 months
Number of subjects: 29
Study 26132314 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance treatment
Number of subjects: 29
Study 26132314 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (previously in a placebo group)
Number of subjects: 29
Study 26132688 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidant personality disorder
Number of subjects: 279
Study 26132688 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional abuse (CTQ-SF subscale)
Number of subjects: 279
Study 26132688 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional abuse moderating effect
Number of subjects: 279
Study 26132688 — intervention group
Group type: COMPARATOR
Intervention: No avoidant personality disorder with emotional abuse
Number of subjects: 279
Study 26133379 — intervention group
Group type: EXPERIMENTAL
Intervention: Active follow-up investigations at months 3, 6, 12, 24, and 36 after diagnosis.
Number of subjects: 2000